The UK's Stem Cell Sciences, which has been commercializing stem cell technology, asked for a temporary suspension in the trading of its shares as it reviews a lineup of strategic options that include a possible sale of assets, refinancing and a merger. SCS says it's already engaged in a number of discussions along those lines.
Just last week Pfizer announced a five-year deal for SCS' research services. And a little more than a week ago it revealed a pair of deals for its technology. One company [1] agreed to pay SCS £480k over six years for access to its technology and CHDI foundation inked a services agreement.
- see the release [2] on the Pfizer deal
- read the report [3] from SmallCapNews
Related Article:
Pfizer launches regenerative medicine unit [4]
Links:
[1] http://www.businessweekly.co.uk/2008111332779/life-sciences/stem-cell-sciences-pumping-out-the-deals.html
[2] http://www.fiercebiotech.com/press-releases/stem-cell-sciences-signs-service-agreement-pfizer-provide-access-proprietary-techno-0
[3] http://www.smallcapnews.co.uk/article/Stem_Cell_Sciences_suspends_trading_ahead_of_review/6182.aspx
[4] http://www.fiercebiotech.com/story/pfizer-launches-regenerative-medicine-unit/2008-11-14